{"timeline":{"defaultZoomLevel":"0","height":600,"asset":{},"date":[{"asset":{"media":"https://static.wixstatic.com/media/5bcc16_2c04b7a348cd4c1d9b0c0e838d398075~mv2.png/v1/fill/w_657,h_691,al_c,q_90,enc_avif,quality_auto/5bcc16_2c04b7a348cd4c1d9b0c0e838d398075~mv2.png","thumbnail":{"path":"images/image-VHJRVAln.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"startDate":"1949,03","headline":"John Cade&#039;s Discovery","text":"<p>Australian psychiatrist John Cade published groundbreaking research demonstrating that lithium salts had a calming effect on manic patients. Using experiments on guinea pigs and then clinical trials, Cade identified lithium’s mood-stabilising properties, marking the first serious evidence of a pharmacological treatment for mania. This discovery paved the way for lithium’s psychiatric use.</p>\n"},{"asset":{"credit":"In numerous public institutions, especially in the 1950s, the sleeping arrangements for patients with mental illness or mental retardation lacked any semblance of privacy or dignity. The above photo is from the June 1961 issue of APA’s journal Mental Hosp","caption":"https://www.psychiatryonline.org/doi/10.1176/appi.pn.2019.3b29","media":"https://www.psychiatryonline.org/cms/10.1176/appi.pn.2019.3b29/asset/images/hospital_beds.jpg","thumbnail":{"path":"images/image-IFBPOj1c.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"startDate":"1950","headline":"Early Clinical Trials Worldwide","text":"<p>Following Cade’s findings, lithium’s potential was quickly explored across continents. Trials in Europe and North America began, assessing efficacy and dosing but also revealing risks of toxicity due to a lack of monitoring protocols. Despite early enthusiasm, lithium’s adoption was inconsistent due to safety concerns.</p>\n"},{"asset":{"media":"https://media.istockphoto.com/id/92019407/photo/danger-drugs.jpg?s=612x612&w=0&k=20&c=ZAOQP-a8ei1dSh7rNGc4JCwt4l2yzwpCjuJRLMYlzng=","credit":"https://www.istockphoto.com/photos/medicine-warning-symbol-danger-warning-sign","thumbnail":{"path":"images/image-borSyNnC.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"startDate":"1960","headline":"1960s - Recognition of Lithium Toxicity and Safety Improvements","text":"<p>Reports of lithium toxicity and deaths led to warnings from regulatory agencies. Researchers developed better understanding of lithium’s narrow therapeutic window. This resulted in the invention of plasma lithium level assays, enabling clinicians to monitor blood levels and adjust dosage, significantly improving safety and outcomes.</p>\n"},{"asset":{"media":"https://logos-world.net/wp-content/uploads/2022/02/FDA-Logo-before-2016.png","credit":"https://logos-world.net/wp-content/uploads/2022/02/FDA-Logo-before-2016.png","thumbnail":{"path":"images/image-6xYhTaO5.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"startDate":"1974,08","headline":"FDA Approval for Mania Treatment","text":"<p>The United States Food and Drug Administration formally approved lithium carbonate for treatment of acute mania, making it the first pharmacological agent officially sanctioned for manic episodes. This approval followed rigorous trials affirming lithium’s therapeutic benefits and established a regulatory foundation for its broader psychiatric use.</p>\n"},{"asset":{"media":"https://static.vecteezy.com/system/resources/previews/019/925/073/large_2x/close-up-hand-man-and-nurse-taking-a-blood-sample-with-vintage-filter-free-photo.jpg","credit":"https://static.vecteezy.com/system/resources/previews/019/925/073/large_2x/close-up-hand-man-and-nurse-taking-a-blood-sample-with-vintage-filter-free-photo.jpg","thumbnail":{"path":"images/image-Z4ZDLr60.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"text":"<p>Clinics began incorporating regular blood tests for lithium plasma levels into standard care. This proactive monitoring reduced adverse events from toxicity and improved dose titration. Routine testing became a cornerstone of lithium therapy, balancing efficacy with patient safety and reinforcing lithium’s reliability as a maintenance treatment.</p>\n","headline":"Routine Serum Lithium Monitoring Introduced","startDate":"1979"},{"asset":{"media":"https://logos-world.net/wp-content/uploads/2022/02/FDA-Logo-before-2016.png","credit":"https://logos-world.net/wp-content/uploads/2022/02/FDA-Logo-before-2016.png","thumbnail":{"path":"images/image-09lSiFZb.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"headline":"FDA Approval for Maintenance Treatment","startDate":"1995,05","text":"<p>Lithium’s indication extended to long-term maintenance therapy for bipolar disorder after the FDA approved it specifically for this use. This decision was based on evidence that sustained lithium treatment reduced recurrence of mood episodes and hospitalisations, solidifying its role beyond acute mania to chronic illness management.</p>\n"},{"asset":{"media":"https://t3.ftcdn.net/jpg/06/64/23/76/360_F_664237691_uz95ZX0vvBGp6Xdl6Obb9y29WuOgoV0h.jpg","credit":"https://t3.ftcdn.net/jpg/06/64/23/76/360_F_664237691_uz95ZX0vvBGp6Xdl6Obb9y29WuOgoV0h.jpg","thumbnail":{"path":"images/image-u4XlfUiP.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"startDate":"2000","headline":"Meta-Analysis of Suicide Risk Reduction","text":"<p>A seminal meta-analysis collated data from multiple studies and demonstrated that patients treated with lithium had a significantly lower risk of suicide compared to those not on lithium. This finding established lithium as unique among mood stabilisers for its protective effect against suicide, influencing clinical guidelines worldwide.</p>\n"},{"asset":{"media":"https://pharmaceutical-journal.com/wp-content/uploads/2023/05/nice-sign.jpg","caption":"https://pharmaceutical-journal.com/wp-content/uploads/2023/05/nice-sign.jpg","thumbnail":{"path":"images/image-m39pf1BG.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"startDate":"2004","text":"<p>The National Institute for Health and Care Excellence (NICE) issued its first evidence-based bipolar disorder guideline, recommending lithium as a first-line maintenance treatment. These guidelines helped standardise lithium prescribing in the UK, emphasizing controlled use, monitoring, and patient education.</p>\n","headline":"First NICE Bipolar Disorder Guidelines"},{"asset":{"media":"https://d2kgiyw8u6fo2v.cloudfront.net/organization-logos/2022_NICE.png","credit":"https://d2kgiyw8u6fo2v.cloudfront.net/organization-logos/2022_NICE.png","thumbnail":{"path":"images/image-EGp4sRLm.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"startDate":"2014","text":"<p>The updated NICE guideline CG185 clarified lithium dosing, monitoring frequency, and target plasma levels. It reinforced lithium’s role in both mania and depression prevention and provided clearer protocols to manage side effects and toxicity risks, integrating the latest research and expert consensus.</p>\n","headline":"Updated NICE Guideline CG185"},{"asset":{"media":"https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSHsmTah9opp5_ESE48XnyrIyw_o-M54C8HgA&s","credit":"https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSHsmTah9opp5_ESE48XnyrIyw_o-M54C8HgA&s","thumbnail":{"path":"images/image-W8HGvn1y.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"headline":"SIGN Guideline 133 Published","startDate":"2014,06","text":"<p>The Scottish Intercollegiate Guidelines Network (SIGN) released guideline 133, offering comprehensive recommendations for lithium use including initiation, shared care, monitoring, and management of adverse effects. SIGN underscored coordinated care models between specialists and primary care for optimal safety and effectiveness.</p>\n"},{"asset":{"media":"https://xtalks.com/wp-content/uploads/2017/01/Neurons600.jpg","caption":"https://xtalks.com/wp-content/uploads/2017/01/Neurons600.jpg","thumbnail":{"path":"images/image-1v1U2pVO.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"headline":"Research into Neuroprotective Effects Begins","startDate":"2015","text":"<p>Studies began investigating lithium beyond mood symptoms, exploring its neurotrophic and neuroprotective properties. Experimental evidence suggested potential benefits in neurodegenerative diseases such as Alzheimer’s and Parkinson’s, sparking interest in lithium’s broader therapeutic role at low doses.</p>\n"},{"asset":{"media":"https://www.madinamerica.com/wp-content/uploads/2021/12/lithum.jpg","credit":"https://www.madinamerica.com/wp-content/uploads/2021/12/lithum.jpg","thumbnail":{"path":"images/image-3mo4jG1M.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"startDate":"2018","headline":"Long-Term Effectiveness Confirmed","text":"<p>Long-term observational studies reinforced lithium’s efficacy in preventing relapse of mood episodes over many years. These data supported the benefits of continued maintenance therapy and informed guideline updates emphasizing adherence and regular monitoring to sustain positive outcomes.</p>\n"},{"asset":{"media":"https://www.thecarlatreport.com/ext/resources/2025/08/14/LithiumOrate_sm.webp?t=1755196975&width=400","credit":"https://www.thecarlatreport.com/ext/resources/2025/08/14/LithiumOrate_sm.webp?t=1755196975&width=400","thumbnail":{"path":"images/image-vIhekPZj.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"startDate":"2020","text":"<p>Emerging research focused on low-dose lithium as a potential intervention to slow cognitive decline and dementia progression. Animal studies and preliminary clinical trials indicated lithium’s ability to protect neuronal integrity and reduce pathological processes, marking a promising new avenue of lithium application.</p>\n","headline":"Low-Dose Lithium and Cognitive Decline Research"},{"asset":{"media":"https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSLvrWzrI4-j8_QlB2OyFIDxD99EcHhbcHYkA&s","credit":"https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcSLvrWzrI4-j8_QlB2OyFIDxD99EcHhbcHYkA&s","thumbnail":{"path":"images/image-IkRs3eVY.jpg","mime":"image/jpeg","copyright":{"license":"U"},"width":32,"height":32}},"headline":"Inclusion in WHO’s Essential Medicines List","startDate":"2023","text":"<p>Lithium carbonate was listed in the World Health Organization’s Model List of Essential Medicines, recognising its critical role in mental health treatment globally. This inclusion highlights lithium’s continued importance in psychiatric care and supports equitable access, especially in low-resource settings.</p>\n"}],"language":"en","headline":"Lithium: A timeline","text":""}}